恶性肿瘤化疗后所致重度血小板减少给予重组人白细胞介素11的临床评价OA
Clinical Evaluation of Using Recombinant Human Interleukin 11 for Malignant Tumor Patients after ;Chemotherapy Induced Severe Thrombocytopenia
目的：评价恶性肿瘤患者在化疗后出现重度血小板减少给予重组人白细胞介素11（rhIL-11）的治疗及预防效果。方法：选择58例恶性肿瘤患者，在化疗后出现重度血小板减少后给予rhIL-11治疗（作为治疗周期）；在下一周期化疗结束后48 h所有患者再给予rhIL-11预防性治疗（作为预防治疗周期）。采用自身的对照研究方法评价2个周期患者血小板减少的程度及持续时间。结果：在治疗周期本组的治疗有效率为100％（58/58），而治疗周期及预防治疗周期用药持续…查看全部>>
Objective:To evaluate the preventive and curative effects of recombinant human interleukin 11 (rhIL-11)for malignant tumor patients after chemotherapy induced severe thrombocytopenia.Method:58 patients with malignant tumor after chemotherapy induced severe thrombocytopenia were enrolled in the study,in the presence of severe thrombocytopenia after treated were given rhIL-11(as treatment period);all the patients in the next cycle of chemotherapy at 48 h after…查看全部>>
武孟宇;姜涛
辽宁省抚顺矿务局总医院药剂科 辽宁 抚顺 113008辽宁省抚顺矿务局总医院药剂科 辽宁 抚顺 113008
恶性肿瘤药物化疗重度血小板减少重组人白细胞介素11
Malignant tumorChemotherapyThrombocytopeniaRecombinant human interleukin 11
《中国医学创新》 2015 (4)
132-134,3
评论